Efficacy of Rifaximin in patients with Irritable Bowel Syndrome and its Comparison with Previous Drugs: A Retrospective Study

Authors
Sangeeta Yadav¹, Omkar Singh², Manoj Kumar³, Ashish Gautam⁴
¹Tutor, Autonomous State Medical College, Firozabad
²Assistant Professor, Autonomous State Medical College, Firozabad
³Associate Professor, Autonomous State Medical College, Firozabad
⁴Associate Professor, SN Medical College, Agra

Abstract
Irritable bowel syndrome often becomes a headache for the patient as well as doctor and till date no drug has proven to be 100% effective in managing these patients. We studied Rifaximin, one of the latest drug for the management of this disorder and compared it with drugs previously used. This study, a combination of retrospective as well as prospective showed that Rifaximin has the most satisfactory results in these patients, however the results were not sustained as with other drugs.

Introduction
I.B.S. is a disorder that leads to abdominal pain and cramping and changes in bowel movements¹ and other symptoms in the absence of any organic cause² or detectable structural abnormality. The IBS is one of the most common chronic medical conditions, yet its cause is unknown. It is a source of chronic pain, fatigue, and other symptoms³,⁴ anxiety, depression⁵,⁶ which may lead to suicide⁷. Proposed factors for suicide are hopelessness and poor quality of services⁸,⁹. Patients with I.B.S. fall into two groups.¹⁰

- Most commonly, patients have abdominal pain associated with altered bowel habits that consist of constipation, diarrhoea, or both.
- In second group, the patients have painless diarrhoea. Painless diarrhoea does not strictly fulfil the Rome-II criteria to be classified as I.B.S.

A large number of drugs have been used for the treatment of IBS till date but none of them has proved to be successful. We studied the effect of Rifaximin in these patients and compared its effect with the drugs previously used. Rifaximin is a semisynthetic antibiotic used for treating traveler’s diarrhoea¹¹ & hepatic encephalopathy.

Material and Methods
Inclusion Criteria
Patients who fulfill the ROME 3 Criteria for diagnosis of IBS-D, or Patients attending the OPD having complaints suggestive of IBS-D and did not respond with oral anti-amoebic and gut specific antibiotics, or Patients previously labeled IBS-D after essential investigations and did not respond with previous treatment and between 20 to 50 years of age were included in the study.
Exclusion Criteria
Patient of IBS-C, IBS-M and IBS-U subtype, those who were taking Theophylline, ATT, narcotics, alosetron, lubiprostone, warfarin, antipsychotics, antispasmodic, antidiarrheal, probiotics. Any gut specific antibiotic and Rifaximin patients with Underlying co morbid conditions that can alter study results like Diabetes mellitus, thyroid dysfunction, HIV, Chronic kidney disease, Chronic liver disease, Abdominal tuberculosis and previous bowel resection or abdominal surgery (except cholecystectomy, appendectomy and pelvic organ surgery or cesarean section).

Study Type
A Hospital based retrospective study with prospective comparative analysis was conducted. Patients who were known case of irritable bowel syndrome attending medicine OPD to consult for present symptoms were enrolled for the study. After detailed evaluation of the previous medical records and confirmation of diagnosis of irritable bowel syndrome, its subtype were categorised. Further investigations to substantiate the diagnosis were done if required. Patients who fulfill the inclusion criteria were asked to bring previous treatment records. All the drugs and non pharmacological measures taken by the patient in past pertaining to the irritable bowel syndrome were recorded. Patients were further asked to stop all previous medications and a recommended dose of Rifaximin i.e. 400 mg TID for 10 days was given.

Study Visits
Patient were called on 10th, 40th, 60th, 75th and 100th day (end of study day for subject) after completion of treatment duration.

Primary Efficacy Evaluation Period
Patients were observed for positive response from 10th to 20th day after initiation of treatment day.

Responses
Patients response was recorded on the same format as done for previous medications.

Follow Up
Patients responded with 2 or 3 on response score were followed for 100 days at definite intervals.

Recording Response

| Level Of Satisfaction | With Rifaximin |
|-----------------------|---------------|
| 0                     | Not satisfied |
| 1                     | Partially satisfied; but less than other medications |
| 2                     | Partially satisfied; equal to other medications |
| 3                     | Partially satisfied; more then previous treatment |
| 4                     | Complete but ill-sustained satisfaction |
| 5                     | Complete and sustained response |

Results
Table 1: Distribution of Study Group According to Age Group and IBS Subtype

| AGE DISTRIBUTION (in Years) | I.B.S. Subtype Diarrhoea Predominant | I.B.S. Subtype Mixed | Total |
|-----------------------------|-------------------------------------|---------------------|-------|
| 0 - 20                      | 4                                   | 3                   | 7     |
| 21 - 30                     | 19                                  | 7                   | 26    |
| 31 - 40                     | 9                                   | 6                   | 15    |
| 41 - 50                     | 1                                   | 5                   | 6     |
| >50                         | 2                                   | 1                   | 3     |

In our study, total number of patients were 57 in which most of the patients were seen in the age group 21 – 40. Mean Age of the group was 31.16 years. Among all patients 35 (61.40 %) were of IBS Subtype Diarrhoea Predominant and 22 (38.60 %) were of IBS Subtype Mixed. So Diarrhoea Predominant IBS Subtype is more common than Mixed type.

Table 2: Distribution of Study group According to sex and level of Satisfaction with Rifaximin

| LEVEL OF SATISFACTION WITH RIFAXIMIN | MALE | FEMALE |
|-------------------------------------|------|--------|
| 0                                   | 3    | 1      |
| 1                                   | 4    | 1      |
| 2                                   | 6    | 7      |
| 3                                   | 5    | 4      |
| 4                                   | 12   | 11     |
| 5                                   | 2    | 1      |
Table 3 - Distribution of study group According to I. B. S. Subtype and level of Satisfaction with Rifaximin

| Level Of Satisfaction With Rifaximin | I. B. S. SUBTYPE - Diarrhoea Predominant | I. B. S. SUBTYPE - Mixed |
|-------------------------------------|------------------------------------------|--------------------------|
| 0                                   | 2                                        | 2                        |
| 1                                   | 1                                        | 4                        |
| 2                                   | 6                                        | 7                        |
| 3                                   | 4                                        | 5                        |
| 4                                   | 19                                       | 4                        |
| 5                                   | 3                                        | 0                        |

Table 4 - Distribution of study group According to level of Satisfaction with Rifaximin at Different Points of the Study

| Level of Satisfaction with RIFAXIMIN | At 10th Day (Number of Patients) | At 40th Day (Number of Patients) | At 60th Day (Number of Patients) | At 75th Day (Number of Patients) | At 100th Day (Number of Patients) |
|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|-----------------------------------|
| 0                                    | 1                                | 2                                | 5                                | 8                                | 20                                |
| 1                                    | 3                                | 7                                | 8                                | 11                               | 13                                |
| 2                                    | 7                                | 8                                | 19                               | 19                               | 10                                |
| 3                                    | 19                               | 20                               | 15                               | 13                               | 11                                |
| 4                                    | 8                                | 20                               | 10                               | 6                                | 3                                 |
| 5                                    | 19                               | 0                                | 0                                | 0                                | 0                                 |

Most of the patients were very much satisfied with Rifaximin at the 10th day of the study. But the level of satisfaction falls progressively as we move to 100th day of the study. So the satisfaction with Rifaximin is good but not sustained.

Table 5: Average Satisfaction with Rifaximin

| STUDY DAYS | AVERAGE SATISFACTION with RIFAXIMIN |
|------------|-------------------------------------|
| 10         | 3.52                                |
| 40         | 2.85                                |
| 60         | 2.29                                |
| 75         | 1.96                                |
| 100        | 1.36                                |

The average level of satisfaction with Rifaximin was 3.52 at the beginning of the study which gradually fall to 1.36 at the end of the study. IT Shows that the Effect of Rifaximin is Good but not Sustained.
Table 6 Average Satisfaction With Different Drugs

| DRUGS                        | AVERAGE SATISFACTION |
|------------------------------|-----------------------|
| RIFAXIMIN                    | 2.89                  |
| LOPERAMIDE                   | 2.24                  |
| PSYLLIUM HUSK                | 2.03                  |
| SMOOTH MUSCLE RELAXANT       | 1.93                  |
| TRICYCLIC ANTIDEPRESSANT     | 2                     |
| SSRIs                        | 1.26                  |
| PROBIOTICS                   | 1.57                  |
| FQ+METROGYL                  | 2.70                  |
| METROGYL                     | 2.63                  |
| PREBIOTICS                   | 2.12                  |

Fig 1 & 2 show that the average level of satisfaction for all the drugs prescribed for IBS patients in which Rifaximin has topped the list followed by the combination of FQ + Metrogyl and then Metrogyl alone, while SSRIs came last among this group. This shows that the use of the antibiotics is relatively more effective in relieving the symptoms of I.B.S. patients than other medicines (loperamide, psyllium husk, smooth muscle relaxants, tricyclic antidepressants, SSRIs, probiotics, prebiotics).

Discussion
Recurrent gut infection and change in gut flora in IBS and use of antibiotics:
Change in gut flora is one of the strongly proposed mechanism behind the development of IBS – D and IBS – M. Table no. – 6: shows Rifaximin and different medications or measures previously prescribed individually on different patients and their average level of satisfaction. As we can see that Rifaximin has topped the list (with average level of satisfaction 2.89) followed by the combination of FQ + Metrogyl and then Metrogyl alone, While SSRIs came last (with average level of satisfaction 1.26) among this group. From the above observation we can see that the use of the antibiotics is relatively more effective in relieving the symptoms of I.B.S. patients than other medicines (loperamide, psyllium husk, smooth muscle relaxants, tricyclic antidepressants, SSRIs, probiotics, prebiotics). This strongly suggest recurrent gut infections as the possible etiopathogenesis for the development of Irritable Bowel Syndrome. This was also shown in a study done by Scarpellini E et al.\textsuperscript{12} in which they observed that Rifaximin was effective and safe in SIBO treatment and IBS symptoms improvement in childhood.

Satisfaction with Rifaximin at different points of the study:
Table no.5 shows average level of satisfaction with Rifaximin at different points of the study.
which shows that the level of satisfaction with Rifaximin was very high at the beginning of the study but it progressively fall when we move towards the end of the study (100th day). It shows that the effect of Rifaximin is good but not sustained. The result of this study contradict the result of previous studies done worldwide. Jiang ZD et al13 (2005) observed that in vitro inhibitory activity of Rifaximin is directed against Gram-positive and Gram-negative, aerobic and anaerobic bacteria. It is effective in the treatment of gastrointestinal infections when given orally because of the high concentration of the drug remaining in the gut lumen. Laboratory investigations have been carried out to assess the in vitro activity of Rifaximin on different bacterial strains isolated from both human and domestic animals. The available data suggest that Rifaximin is active in vitro and in vivo in the treatment of bacterial infection of adults and children. Pimentel M et al14 observed in their study that among patients who had IBS without constipation, treatment with Rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. Schey R15 et al concluded in a study that a 2-week course of Rifaximin provided significant relief of IBS symptoms, as well as bloating and abdominal pain.

The possible reasons behind contradictory results of our study from previous study results may be:-

1. The studies done previously were from developed countries where incidences of recurrent G.I. infections are very less.
2. Our study is done in a Tropical country where the incidences of recurrent gut infections are very high.
3. Our study group size is very small in comparison to the other studies done worldwide.

**IBS Subtypes and sex of the patient**

Our study shows that among Males, Diarrhoea Predominant IBS Subtypes is more common. While among Females Mixed IBS Subtype is slightly more common which is supported by the previous studies. Our study also shows that males are more affected than females which is contradicted by the previous studies. It may be due to the small size of our study. In a study by Sun-Young Lee et al16 out of 253 women and 252 men, 4150.8% of women were diagnosed as IBS, while 35.8% of men were diagnosed as IBS (p=0.01). With aspect to the IBS subtypes, the diarrhoea-dominant type was more common in men, while constipation dominant or alternating types were more common in women (p<0.001). The increased prevalence of IBS in women may be related to psychosocial factors rather than differences in colonic motor function because there is no gender differences in visceral perception.

**IBS subtypes and satisfaction with Rifaximin**

Most of the patients of diarrhoea predominant subtype have level of satisfaction 4 with Rifaximin while most of the patients of Mixed subtype have level of satisfaction 2. So patients of diarrhoea predominant subtype are more satisfied with Rifaximin than Mixed type.

**Sex of the Patient and Satisfaction with Rifaximin**

No difference was found between male and female patients regarding the effect of Rifaximin.

**Conclusion**

Prominent reason behind the higher satisfaction rate with antibiotic predominantly Rifaximin and also with others is due to the fact that most of the cases in India are infection related. Rifaximin has been used extensively in IBS disease in the past with successful results. However in India results are of much greater significance as predominant underlying cause of IBS is infection related. More over greater satisfaction was seen with IBS-D type.

**References**

1. Schmulson MW, Chang L (1999). "Diagnostic approach to the patient with irritable bowel syndrome". *Am. J. Med.* 107(5A): 20S–26S.
doi:10.1016/S0002-9343(99)00278-8. PMID 10588169.
2. Malagelada, JR (2006). "A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation". *International journal of clinical practice* 60(1): 57–63. doi:10.1111/j.1368-5031.2005.00744.x. PMID 16409429.
3. Paré P, Gray J, Lam S et al. (2006). "Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study". *Clinical therapeutics* 28 (10): 1726–35; discussion 1710–1. doi:10.1016/j.clinthera.2006.10.010. PMID 17157129.
4. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R (2006). "Costs of irritable bowel syndrome in the UK and US". *Pharmacoeconomics* 24 (1): 21–37. doi:10.2165/00019053-200624010-00002. PMID 1645300.
5. "IBS and Depression Connection and Treatments". Webmd.com. Retrieved 2012-10-21.
6. Thabane M, Kottachchi DT, Marshall JK (2007). "Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome". *Aliment Pharmacol Ther* 26 (4): 535–44. doi:10.1111/j.1365-2036.2007.03399.x. PMID 17661757.
7. Vorous, Heather Van (19uu). *Eating for I.B.S.* Marlowe & Co.: Marlow & Co. ISBN 1569246009.
8. Miller, V; Hopkins, L; Whorwell, PJ (2004 Dec). "Suicidal ideation in patients with irritable bowel syndrome.". *Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association* 2 (12): 1064–8. PMID 15625650.
9. Spiegel, B; Schoenfeld, P; Naliboff, B (2007 Jul 15). "Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome.". *Alimentary pharmacology & therapeutics* 26 (2): 183–93. PMID 17593064.
10. Holten KB, Wetherington A, Bankston L (2003). "Diagnosing the patient with abdominal pain and altered bowel habits: is it irritable bowel syndrome?". *Am Fam Physician* 67 (10): 2157–62. PMID 12776965.
11. DuPont HL, Jiang ZD, Okhuysen PC. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med. 2005 May 17, 142(10):805-12.
12. Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundaro C, Gasbarrini A. Eur Rev Med Pharmacol Sci. 2013 May;17(10):1314-20.
13. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity—a review. Chemotherapy. 2005;51 Suppl 1:67-72.
14. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Borley E, Forbes WP. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.
15. Schey R, Rao SS. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):461-4. doi: 10.1586/ehg.11.50.
16. Lee SY, Kim JH, Sung IK, Park HS, Jin CJ, Choe WH, Kwon SY, Lee CH, Choi KW. Irritable bowel syndrome is more common in women regardless of the menstrual phase: a Rome II-based survey. J Korean Med Sci. 2007; 22(5):851–854. doi: 10.3346/jkms.2007.22.5.851.